Karyopharm defers debt payments, requires $25M equity raise to extend runway past mid-2026

Karyopharm Therapeutics Inc.

Second Amendment to Credit Agreement defers June 2026 principal payment to September 10, 2026; interest due June 30 paid in kind.
Minimum liquidity covenant reduced to $10M through Oct 10, 2026 (from $25M) conditional on $25M+ equity raise before June 10, 2026.
Forbearance agreements with lenders and noteholders defer payment-related defaults through Sep 30, 2026, and liquidity covenant breaches through Oct 10, 2026.
Phase 3 XPORT-EC 042 top-line data still expected mid-2026; the amendments aim to extend cash runway beyond that readout.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Karyopharm Therapeutics Inc. amended Second Amendment to Credit and Guaranty Agreement with Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (effective 2026-02-27).

Action: amendment
Agreement: credit facility
Counterparty: Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001503802-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.